Amylyx Pharmaceuticals, Inc. 8-K

What Happened

• On January 8, 2026 Amylyx Pharmaceuticals (AMLX) filed a Form 8-K disclosing two items: an updated corporate presentation (Regulation FD disclosure, Exhibit 99.1) and the selection of AMX0318, a long‑acting GLP‑1 receptor antagonist, as a development candidate for post‑bariatric hypoglycemia and other rare diseases.
• AMX0318 was discovered through a research collaboration with Gubra A/S. The candidate handover triggers a $4.0 million milestone payment to Gubra, and under the collaboration Gubra is eligible for more than $50 million in success‑based development and commercialization milestones plus mid‑single‑digit royalties on worldwide net sales.

Key Details

• Filing date: January 8, 2026 (Form 8‑K).
• Development candidate: AMX0318 — long‑acting GLP‑1 receptor antagonist for post‑bariatric hypoglycemia and other rare diseases.
• Collaboration terms noted: $4.0M immediate milestone payment to Gubra upon handover; Gubra eligible for >$50M in future milestones and mid‑single‑digit royalties.
• Exhibit filed: 99.1 — updated corporate presentation furnished with the 8‑K.

Why It Matters

• This advances Amylyx’s early‑stage pipeline by adding a new development candidate for a rare metabolic complication (post‑bariatric hypoglycemia), which could expand the company’s therapeutic focus beyond its existing programs.
• The agreement creates near‑term contractual cash obligations (the $4M payment) and potential future milestone and royalty liabilities tied to AMX0318’s development and commercialization — important for investors monitoring R&D spend and future revenue sharing.
• The furnished corporate presentation (Reg FD) may contain additional strategic or program updates for investors; review Exhibit 99.1 for more context.